{"pmid":32314010,"title":"Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","text":["Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.","Rheumatol Int","Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho","32314010"],"abstract":["In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications."],"journal":"Rheumatol Int","authors":["Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314010","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s00296-020-04584-7","keywords":["covid-19","coronavirus","disease-modifying antirheumatic drugs","pneumonia","rheumatoid arthritis"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China","myalgia"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination","Hydroxychloroquine"],"_version_":1664714520041357312,"score":8.518259,"similar":[{"pmid":32205186,"pmcid":"PMC7102591","title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","text":["COVID-19 infection and rheumatoid arthritis: Faraway, so close!","The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients.","Autoimmun Rev","Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto","32205186"],"abstract":["The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients."],"journal":"Autoimmun Rev","authors":["Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205186","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.autrev.2020.102523","keywords":["COVID-19","Coronavirus","Cytokine release syndrome","DMARDs","Rheumatoid arthritis","Treatment"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352133689278465,"score":335.3954},{"pmid":32100486,"pmcid":"PMC7082663","title":"2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings.","text":["2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings.","From December 2019, Coronavirus disease 2019 (COVID-19) pneumonia (formerly known as the 2019 novel Coronavirus [2019-nCoV]) broke out in Wuhan, China. In this study, we present serial CT findings in a 40-year-old female patient with COVID-19 pneumonia who presented with the symptoms of fever, chest tightness, and fatigue. She was diagnosed with COVID-19 infection confirmed by real-time reverse-transcriptase-polymerase chain reaction. CT showed rapidly progressing peripheral consolidations and ground-glass opacities in both lungs. After treatment, the lesions were shown to be almost absorbed leaving the fibrous lesions.","Korean J Radiol","Wei, Jiangping","Xu, Huaxiang","Xiong, Jingliang","Shen, Qinglin","Fan, Bing","Ye, Chenglong","Dong, Wentao","Hu, Fangfang","32100486"],"abstract":["From December 2019, Coronavirus disease 2019 (COVID-19) pneumonia (formerly known as the 2019 novel Coronavirus [2019-nCoV]) broke out in Wuhan, China. In this study, we present serial CT findings in a 40-year-old female patient with COVID-19 pneumonia who presented with the symptoms of fever, chest tightness, and fatigue. She was diagnosed with COVID-19 infection confirmed by real-time reverse-transcriptase-polymerase chain reaction. CT showed rapidly progressing peripheral consolidations and ground-glass opacities in both lungs. After treatment, the lesions were shown to be almost absorbed leaving the fibrous lesions."],"journal":"Korean J Radiol","authors":["Wei, Jiangping","Xu, Huaxiang","Xiong, Jingliang","Shen, Qinglin","Fan, Bing","Ye, Chenglong","Dong, Wentao","Hu, Fangfang"],"date":"2020-02-27T11:00:00Z","year":2020,"_id":"32100486","week":"20209|Feb 24 - Mar 01","doi":"10.3348/kjr.2020.0112","keywords":["2019-ncov","covid-19","coronavirus","pneumonia","tomography, x-ray computed"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875150442497,"score":276.28415},{"pmid":32312064,"title":"Coronavirus disease 2019 (COVID-19): two case reports from a family cluster.","text":["Coronavirus disease 2019 (COVID-19): two case reports from a family cluster.","The coronavirus disease 2019 (COVID-19) is a new infectious disease, firstly appeared in Wuhan city and has rapidly spread to 114 countries outside China, which is receiving worldwide attention. As two important means of examination, computed tomography (CT) and real-time reverse transcription polymerase chain reaction (RT-PCR) have always been controversial in the clinical diagnosis of COVID-19 pneumonia. Here, we report a family cluster case of a father and a son diagnosed as COVID-19 at our hospital, and described the clinical manifestations, laboratory results, CT changes, diagnosis and treatment strategy of these two patients. Focus on the value of these two methods in the diagnosis and treatment of diseases, as well as their respective deficiencies. For patient 1 (father), the efficacy of RT-PCR is not satisfactory either in terms of diagnosis or follow-up, which may cause misdiagnosis and delay treatment. For patient 2 (son), the clinical symptoms were not obvious, but CT imaging clearly displayed dynamic changes of the lung lesions. Meanwhile, the two patients respectively underwent five chest CT examinations during their hospitalization and discharge follow-up, showing the potential harm of radiation. Therefore, in clinical work, doctors should make full use of the advantages of CT and RT-PCR, and take other measures to make up for their disadvantages.","Ann Palliat Med","Tang, Lei","Ye, Zheng","Huang, Zixing","Zeng, Xianchun","Wang, Tao","Xu, Rui","Wang, Rongpin","Song, Bin","32312064"],"abstract":["The coronavirus disease 2019 (COVID-19) is a new infectious disease, firstly appeared in Wuhan city and has rapidly spread to 114 countries outside China, which is receiving worldwide attention. As two important means of examination, computed tomography (CT) and real-time reverse transcription polymerase chain reaction (RT-PCR) have always been controversial in the clinical diagnosis of COVID-19 pneumonia. Here, we report a family cluster case of a father and a son diagnosed as COVID-19 at our hospital, and described the clinical manifestations, laboratory results, CT changes, diagnosis and treatment strategy of these two patients. Focus on the value of these two methods in the diagnosis and treatment of diseases, as well as their respective deficiencies. For patient 1 (father), the efficacy of RT-PCR is not satisfactory either in terms of diagnosis or follow-up, which may cause misdiagnosis and delay treatment. For patient 2 (son), the clinical symptoms were not obvious, but CT imaging clearly displayed dynamic changes of the lung lesions. Meanwhile, the two patients respectively underwent five chest CT examinations during their hospitalization and discharge follow-up, showing the potential harm of radiation. Therefore, in clinical work, doctors should make full use of the advantages of CT and RT-PCR, and take other measures to make up for their disadvantages."],"journal":"Ann Palliat Med","authors":["Tang, Lei","Ye, Zheng","Huang, Zixing","Zeng, Xianchun","Wang, Tao","Xu, Rui","Wang, Rongpin","Song, Bin"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312064","week":"202017|Apr 20 - Apr 26","doi":"10.21037/apm.2020.03.34","keywords":["coronavirus disease 2019 (covid-19)","case report","coronavirus","pneumonia"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664714520066523136,"score":252.02206},{"pmid":32331519,"title":"Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.","text":["Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.","BACKGROUND: COVID-19 pandemics is a challenge for public health and infectious diseases clinicians, especially for the therapeutical approach that is not yet adequately defined. Amid this situation, investigational agents are being used, including chloroquine. We report here the clinical features and therapeutic course of the first reported patient with confirmed COVID-19 pneumonia that recovered in Colombia, after the use of chloroquine and clarithromycin. CASE PRESENTATION: A 34-year-old male, returning from Spain, presented with complaints of fever, and cough, and class-II obesity, being hospitalized. The respiratory viruses and bacteria tested by FilmArray((R)) PCR were negative. Two days later, clarithromycin was started because the patient was suspected as community-acquired pneumonia. At the third day, the rRT-PCR confirmed the SARS-CoV-2 infection. A day later, chloroquine was started because of that. His chest computed tomography was performed and showed bilateral multifocal ground-glass opacities with consolidation, which suggested viral pneumonia as a differential diagnosis. Progressively his clinical condition improved and at day 9, patient rRT-PCR for SARS-CoV-2 became negative. The patient was discharged and isolated at home per 14 days. CONCLUSIONS: Our patient improved significantly. This and other COVID-19 cases are urgently demanding results from clinical trials that support evidence-based therapeutical approaches to this pandemic and the clinical management of patients, especially those at critical care.","Ann Clin Microbiol Antimicrob","Millan-Onate, Jose","Millan, William","Mendoza, Luis Alfonso","Sanchez, Carlos Guillermo","Fernandez-Suarez, Hugo","Bonilla-Aldana, D Katterine","Rodriguez-Morales, Alfonso J","32331519"],"abstract":["BACKGROUND: COVID-19 pandemics is a challenge for public health and infectious diseases clinicians, especially for the therapeutical approach that is not yet adequately defined. Amid this situation, investigational agents are being used, including chloroquine. We report here the clinical features and therapeutic course of the first reported patient with confirmed COVID-19 pneumonia that recovered in Colombia, after the use of chloroquine and clarithromycin. CASE PRESENTATION: A 34-year-old male, returning from Spain, presented with complaints of fever, and cough, and class-II obesity, being hospitalized. The respiratory viruses and bacteria tested by FilmArray((R)) PCR were negative. Two days later, clarithromycin was started because the patient was suspected as community-acquired pneumonia. At the third day, the rRT-PCR confirmed the SARS-CoV-2 infection. A day later, chloroquine was started because of that. His chest computed tomography was performed and showed bilateral multifocal ground-glass opacities with consolidation, which suggested viral pneumonia as a differential diagnosis. Progressively his clinical condition improved and at day 9, patient rRT-PCR for SARS-CoV-2 became negative. The patient was discharged and isolated at home per 14 days. CONCLUSIONS: Our patient improved significantly. This and other COVID-19 cases are urgently demanding results from clinical trials that support evidence-based therapeutical approaches to this pandemic and the clinical management of patients, especially those at critical care."],"journal":"Ann Clin Microbiol Antimicrob","authors":["Millan-Onate, Jose","Millan, William","Mendoza, Luis Alfonso","Sanchez, Carlos Guillermo","Fernandez-Suarez, Hugo","Bonilla-Aldana, D Katterine","Rodriguez-Morales, Alfonso J"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32331519","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s12941-020-00358-y","keywords":["chloroquine","colombia","coronavirus disease 2019 (covid-19)","latin america","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Colombia","Spain","Colombia"],"countries":["Spain","Colombia"],"countries_codes":["ESP|Spain","COL|Colombia"],"e_drugs":["Clarithromycin","Chloroquine"],"_version_":1665071049689006080,"score":251.70633},{"pmid":32314799,"title":"Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","text":["Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R","32314799"],"abstract":["Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314799","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25907","keywords":["coronavirus","disease control","immune responses","immunodulators","interleukin","virus classification"],"source":"PubMed","topics":["Case Report"],"weight":1,"e_drugs":["tocilizumab"],"_version_":1664714520108466176,"score":245.5078}]}